Ask HopeStage to help me review this study
This study may no longer be open, but we can help you understand it and find similar studies.
Study ID: NCT06655688. We help you review the study, but cannot decide medical eligibility.
CompletedNCT06655688
Acceptance and Commitment Therapy (ACT) for Family Members After a First Psychotic Attack
This study is completed. It focuses on schizophrenia and currently lists study information in Turkey.
Schizophrenia, Family Members, ...OtherFrom 18 Years to 65 Years
Key information made simple
What is this study testing?
This study is testing whether a therapy or guided support program may be useful for adults experiencing schizophrenia.
What would participation involve?
Participants may take part in a therapy or guided support program, complete questionnaires or follow-up assessments, attend study visits with the research team. The registry lists locations in Türkiye.
Who is it mainly for?
This study appears to be mainly for adults with schizophrenia.
What should you check before joining?
Ask about how many sessions are required and who delivers them, whether there is a comparison group, how many visits or travel steps are needed, the exact eligibility criteria.
Your next step
The official record suggests a mix of remote and in-person participation through a hospital, with sites including Saglik Bilimleri Universitesi in Istanbul. Participation appears to involve assessments along with scans or samples to help researchers understand patterns more clearly. The main fit is usually matching the main diagnosis and meeting the main study requirements, while common reasons not to take part include other factors that could make participation unsuitable. The official record does not list a formal phase, which usually means this is focused more on feasibility, delivery, or support than a standard drug-development stage.
Questions to ask before joining
- What are the exact eligibility criteria, and what could exclude someone?
- How many visits, assessments, or follow-ups are expected, and over what period?
- What risks, side effects, practical burdens, or alternatives should be understood first?
- Who should be contacted to confirm locations, timing, compensation, and next steps?
Things to check before joining
Study start dateStarted: October 20, 2024
- Recruitment status
- Completed
- Estimated enrollment
- Not clearly listed
- Sponsor
- Saglik Bilimleri Universitesi
- Sponsor type
- Unknown or unclear
- Study type
- Other
- Intervention type
- Other / unclear
- Study phase
- Not clearly listed
- Locations
- Türkiye
- Age range
- From 18 Years to 65 Years
- Official registry ID
- NCT06655688
- Official title
- Acceptance and Commitment Therapy (ACT) for Family Members After a First Psychotic Attack
- Official source
- Official registry link
Ask HopeStage to help me review this study
This study may no longer be open, but we can help you understand it and find similar studies.
Study ID: NCT06655688. We help you review the study, but cannot decide medical eligibility.
For you
Taking part may help clarify how this condition is measured or understood.
It requires regular visits and structured follow-up.
Mixes in-person and remote participation.
Not medical advice
Information from public sources. Are you the study sponsor? Contact us to update this page: hi@hopestage.com
Questions about this study
What is this study trying to understand?
This study is exploring blood test or biological sample for people with schizophrenia. Participants may complete study visits, assessments, or follow-up activities defined by the research team. Direct benefit is not guaranteed. The detailed objective is not always clearly listed in the public registry; the study team can confirm.
Why is the study type not clearly categorized?
The study type is not clearly categorized in the public registry. Focus on the objective, required tasks, visits, any intervention, and eligibility criteria, then ask the study team to confirm.
Who might this study be for?
This study may concern people with schizophrenia; age range: From 18 Years to 65 Years. The criteria appear fairly specific, but you should not assume you are eligible. The study team must confirm diagnosis, age, exclusions, available locations, and next steps.
What would I likely need to do?
The public registry does not clearly describe all participation steps. The listed study locations suggest that at least part of participation may involve a physical site. Ask whether some steps can be done remotely.
What risks or points should I check?
The public registry does not make the main risk category clear. Ask the study team what activities are required, what could feel uncomfortable, how safety is monitored, and what happens if you want to stop. For any mental health study, also ask who to contact if you feel worse, whether participation may affect current treatment, whether you can stop, and who confirms eligibility.
Will I need to travel or attend in-person visits?
The listed study locations suggest that at least part of participation may involve a physical site. Ask which sites are open, how many visits are expected, whether any steps can be done remotely, and whether travel costs or compensation are listed.
Who is behind this study?
This study is sponsored by Saglik Bilimleri Universitesi, which appears to be unknown or unclear. If available, it can be useful to check the sponsor website, collaborators, investigator affiliation, and the official registry before deciding. HopeStage does not judge the quality of a sponsor or researcher, but helps you identify what to verify.
Can I still join this study?
The registry indicates that this study is completed. It may still be useful for understanding the research, but you are unlikely to be able to join.
Want to find a study that may fit you better?
Answer a few simple questions to explore HopeStage studies by condition, country, and situation.
Find a study that may fit meExplore related studies
Other studies that may be relevant based on condition, country, or study type.
CompletedNCT05693935
TV-44749 for schizophrenia
This study is completed in the United States, in Bulgaria, in China, .... It is testing TV-44749 for schizophrenia.
CompletedNCT03345342
Paliperidone Palmitate 6-Month Formulation
This study is completed in the United States, in Australia, in France, .... It focuses on Schizophrenia.
CompletedNCT02713282
Transition to the Paliperidone Palmitate 3-Month Formulation for schizophrenia
This study is completed in France, in the United Kingdom, in Croatia, .... It is testing Transition to the Paliperidone Palmitate 3-Month Formulation for schizophrenia.